The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption
Abstract
Interrupting the renin-angiotensin system (RAS) with a usual daily dose of a single-site RAS inhibitor does not achieve complete and long-lasting pharmacologic blockade. Hormonal and BP effects were compared for 48 h after administration of single oral doses of 300 mg (high dose) of the renin inhibitor aliskiren (A300) and 160 mg (standard antihypertensive dose) of the AT1 receptor antagonist valsartan (V160) and their combination each at half dose (A150+V80) in 12 mildly sodium-depleted normotensive individuals. In this double-blind, placebo-controlled, randomized, four-period crossover study, A300 decreased plasma renin activity and angiotensin I and II levels for 48 h, stimulated immunoreactive active renin release more strongly than V160, and decreased urinary aldosterone excretion for a longer duration than V160. In contrast to V160, the A150+V80 combination did not increase plasma angiotensins. The renin and aldosterone effects of the A150+V80 combination were similar to those of A300 and greater than those of V160. When plasma drug concentrations were taken into account, the A150 +V80 combination had a synergistic effect on renin release. The A150+V80 combination lowered BP at least as effectively as either higher dose monotherapy. In conclusion, in mildly sodium-depleted normotensive individuals, the long-lasting effects of aliskiren alone or in combination with valsartan on plasma immunoreactive active renin and urinary aldosterone effects demonstrate strong and prolonged blockade of angiotensin II at the kidney and the adrenal level. Moreover, a renin inhibitor and AT1R antagonist combination may provide synergistic effects on RAS hormone levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McMurray, J. J., Östergren, J., Swedberg, K., Granger, C. B., Held, P., Michelson, E. L., Olofsson, B., Yusuf, S., & Pfeffer, M. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14283-3 · Cited by 2,604
Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods.
Aickin, M., & Gensler, H. (1996) · American Journal of Public Health · doi:10.2105/ajph.86.5.726 · Cited by 1,346
Cited by
The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease
Remuzzi, G., Perico, N., Macia, M., & Ruggenenti, P. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.09911.x · Cited by 505
Oparil, S., Yarows, S. A., Patel, S., Fang, H., Zhang, J., & Satlin, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61124-6 · Cited by 444
The incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Zhang, Z., Zhang, Y., Ning, G., Deb, D. K., Kong, J., & Li, Y. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803751105 · Cited by 289
Villamil, A., Chrysant, S. G., Calhoun, D., Schober, B., Hsu, H., Matrisciano-Dimichino, L., & Zhang, J. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3280103a6b · Cited by 285
Metadata
- Authors
- Azizi, M., Ménard, J., Bissery, A., Guyenne, T.-T., Bura-Rivière, A., Vaidyanathan, S., & Camisasca, R. P.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2004-12
- Volume
- 15
- Issue
- 12
- Pages
- 3126-3133
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2164834486
- Cited by
- 234
- References
- 2
- FWCI
- 13.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption. https://app.cochat.ai/papers/10.1097/01.asn.0000146686.35541.29
- The paper
- Azizi, M., Ménard, J., Bissery, A., Guyenne, T.-T., Bura-Rivière, A., Vaidyanathan, S., & Camisasca, R. P. (2004). Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000146686.35541.29
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.